News
Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the ...
Shares of Sarepta Therapeutics (NASDAQ:SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
1h
Barchart on MSNStocks Rally on Positive Tariff News ad Rate Cut HopesThe S&P 500 Index ($SPX) (SPY) today is up +0.48%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.39%, and the Nasdaq ...
Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...
Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...
18hon MSN
This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged ...
Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...
The cost of high-end, breakthrough medications traumatizes patients and their families. According to USAfacts, “national ...
Review Sarepta Therapeutics Inc (SRPT:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results